ABCC5 and hepatocellular carcinoma: This approach offers new perspectives on the re-utilization of ZDV and other nucleoside analogs in HCC treatment, emphasizing the importance of targeting the transporter protein ABCC5 to improve drug delivery and overcome cancer drug resistance (12).